has organized an international interlaboratory proficiency testing (PT) programme for measurement of antifungal drugs in plasma. We describe the 5 year results of the laboratories' performance.
Introduction
There has been increasing interest in the analysis of antifungal drug concentrations in recent years. A variety of analytical methods have been published for the quantification of these drugs in human plasma. 1, 2 These analytical methods can be used to study pharmacokinetic behaviour and to characterize drug interactions among antifungal drugs. Several antifungal drugs show large inter-patient variability in pharmacokinetics, whereas evolving data show an association between plasma concentrations and treatment efficacy or toxicity. 3, 4 This advocates the use of therapeutic drug monitoring (TDM), especially for the azoles itraconazole, posaconazole, voriconazole and flucytosine. 3 -8 TDM allows a clinician to individualize the dosage based on drug concentration measurements and thereby helps to optimize the balance between the efficacy and tolerability of the drugs involved. In fact, TDM of azoles has been recommended in the updated guidelines for the treatment of invasive aspergillosis by the Infectious Diseases Society of America (IDSA). 9 Proficiency testing (PT) or external quality control is a valuable tool in the quality improvement process for the analysis of drugs in plasma, enabling laboratories to assess and improve their performance with respect to the bioanalysis of drugs. In addition, an interlaboratory (external) PT programme is essential to verify whether TDM results conform to expectations of the quality required for patient care. In the current analysis we evaluated 5 year data of the PT programme (2008 -12) . Our aim was to assess the overall performance of laboratories, as well as possible explanations for inaccuracies. More specifically, these data allowed us to assess whether laboratory performance was dependent on the antifungal drugs measured, their concentrations, analytical techniques used and the laboratory that performed the analyses.
Methods

Design of the PT programme
The design of the programme was described previously. 11 In summary, drug-free plasma from healthy volunteers was obtained from the Dutch Blood Bank and spiked with high and low concentrations of antifungal drugs. The programme started with the following five azole antifungal drugs and metabolites: fluconazole, itraconazole, hydroxyitraconazole, voriconazole and posaconazole. After 2 years, flucytosine was added to the programme. The sample volume was 3 mL. High and low concentrations were based on concentrations generally achieved in clinical practice after oral or intravenous administration of the selected antifungal drugs (Table 1) .
After the samples were analysed with our own validated methods as a confirmative check (allowing ≤5% deviation from the weighed-in concentrations), they were released into the PT programme. Stability was proven for at least 14 days at various conditions (2408C, 48C and at ambient temperature with daylight) and after three freeze-thaw cycles, supporting the dispatch of samples at room temperature and transport within cold aircraft cargo holds. Samples were sent around twice a year. Laboratories were requested to report their results and provide details about their analytical assays within 6 weeks after dispatch of the samples. These results were recorded anonymously in a central database. Feedback was provided to participating laboratories within 3 months after the deadline of a single round.
After round 2 in 2012, an error evaluation form together with laboratories' individual results from previous rounds was sent to all participating laboratories, regardless of their performance. Based on the CLSI guideline Using Proficiency Testing to Improve the Clinical Laboratory-Second Edition: Approved Guideline GP27-A2, 12 the error evaluation form specified clerical activities associated with the test (C), technical operation of method (T), methodological problems (M), equipment problems (E), organizational factors (O) and other problems. Laboratories were asked to complete the error form for each drug that was analysed in the past.
Results were recorded anonymously.
Statistical analysis
Descriptive statistics were performed after standardization of all laboratory results to percentages with reference to the weighed-in concentrations. The relative deviation from the weighed-in concentration (inaccuracy) was determined by subtraction of 100% from these percentages. The absolute inaccuracy was defined as the absolute deviation from the weighed-in concentration. Concentrations reported within 20% limits around the weighed-in concentrations were considered to be accurate, based on guidelines for bioanalytical method validation and maximum allowable error specifications for drug measurements defined by the US Clinical Laboratory Improvement Amendments (CLIA) of 1988. 13, 14 Results of the programme were presented descriptively and no inferential statistics were performed as available data related to all PT measurements rather than a sample. Differences in accuracy related to the drug to be analysed, concentration, method of analysis and performing laboratory were presented. Four-way ANOVA was conducted to disentangle the simultaneous effects of these factors on the absolute inaccuracy. All statistical analyses were performed using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA). A P value of ,0.05 was considered statistically significant.
Results
Participating laboratories and overall results
The programme started in 2008 with 35 participants. By the end of 2012, 57 laboratories from four different continents Table S1 (available as Supplementary data at JAC Online)]. Over 5 years, 10 laboratories withdrew from participation in the programme and 32 new members joined the programme. A total of 2251 results were reported between 2008 and 2012. Most results were reported for voriconazole, representing 29.0% (n ¼ 652) of the total number of analyses. This was followed by itraconazole (20.0%, n ¼ 451), posaconazole (17.9%, n ¼ 402), hydroxyitraconazole (15.5%, n ¼ 348), fluconazole (12.7%, n ¼ 287) and flucytosine (4.9%, n ¼ 111; Table 2 ). Conventional HPLC was most frequently used (55.0%), followed by LC-MS(/MS) (43.4%), UPLC (1.4%) and GC-MS (0.2%) see Table 2 . For the analysis of antifungal drugs in 2012 (round 10), laboratories used conventional HPLC (n ¼ 27) with fluorescence, UV or photodiode array detection, followed by LC-MS(/MS) (n ¼ 14), UPLC-MS (n ¼ 1) or a combination of these analytical methods (n¼ 15).
Overall, 80.8% of the 2251 analyses were within the predefined range of 80% -120% and thus were considered to be accurate. For those analyses outside the predefined range, 11.5% were ,80% and 7.7% were .120% of the weighed-in range ( Table 2 ). The median absolute inaccuracy for all analyses was 8.0% (IQR 13.0%; range 0.0% -3340.0%). 
Results by antifungal drug
A relatively small difference in median absolute inaccuracy was found between the individual antifungal drugs: fluconazole (6.4%; 0%-96.3%), voriconazole (6.6%; 0%-852.4%), flucytosine (7.8%; 0% -52.5%), posaconazole (9.0%; 0% -960.0%), itraconazole (9.4%; 0%-3340.0%) and hydroxyitraconazole (10.4%; 0%-1620.0%); see Table 2 . In line with this, fluconazole had the highest percentage of accurate analyses (87.5%), followed by voriconazole (86.2%), itraconazole (78.0%), hydroxyitraconazole (77.3%), flucytosine (76.6%) and posaconazole (74.6%; Table 2 ).
Results by concentration
Laboratories analysed a roughly equal number of low and high concentrations over time (1106 and 1145 analyses, respectively). High concentrations were reported with a slightly lower median absolute inaccuracy than low concentrations: 7.3% (range 0.0% -530.1%) versus 9.3% (range 0.0% -3340.0%) respectively. In addition, 24.9% of all low concentrations were reported as inaccurate (i.e. outside the 20% limits of the weighed-in concentrations) versus 13.7% of high concentrations.
Fluconazole had the lowest median absolute inaccuracy for low concentrations (6.7%), followed by voriconazole (8.0%), itraconazole (10.0%), posaconazole (11.0%), hydroxyitraconazole (11.1%) and flucytosine (11.5%). For high concentrations, voriconazole was analysed most accurately, with a median absolute inaccuracy of 5.7%, followed by fluconazole (6.2%), flucytosine (6.7%), posaconazole (8.0%), itraconazole (8.5%) and hydroxyitraconazole (10.3%; Figure 2 ).
Results by analytical method
Median absolute inaccuracy was 8.1% (0.0% -1620.0%; n¼ 1238) for HPLC, 7.8% (0.0% -3340.0%; n ¼ 977) for LC-MS(/MS), 5.0% (0.0% -194.7%; n ¼ 31) for UPLC and 13.3% (3.02% -35.6%; n ¼ 5) for GC-MS. The percentage of accurate analyses was 78.4% for HPLC, 83.8% for LC-MS(/MS), 83.9% for UPLC and 60.0% for GC-MS.
Results by performing laboratory
The results by performing laboratory are presented for the most recent time period, considering that the performance of laboratories may change over time. Median absolute inaccuracy per laboratory participating in rounds 9 and 10 of the PT programme (2012; 671 analyses) ranged between 0.8% and 17.4%. Among all participating laboratories, 41.5% had all analyses within the 20% limits (1 -24 analyses, 267 analyses in total). The performance of the remaining 58.5% of laboratories (404 analyses) ranged from 6.7% inaccurate results (15 analyses) to 75% inaccurate results (4 analyses). Lempers et al.
Analysis of variance on antifungal drug, concentration, method of analysis and laboratory
Four-way ANOVA was performed to assess the effect of the factors antifungal drug, concentration, analytical method and laboratory on absolute inaccuracy. A significant main effect of performing laboratory on absolute inaccuracy was found (F ¼ 2.083, P, 0.005). Other factors did not affect the absolute inaccuracy and no interaction between factors was observed. This was to be expected, considering the large variability in median absolute inaccuracy among laboratories during the years of the programme and the small effect of other factors found in the descriptive analyses presented above.
Sources of error
Twenty-three out of 57 laboratories (40.4%) returned error forms related to 769 out of 2251 analyses (34.2%). Of these analyses, 125 (16.3%) were inaccurate and could be used to identify a total of 104 possible sources of error. Every single reported source of error is included in Table 3 [23 unique sources of error; see Table S2 (available as Supplementary data at JAC Online) for comprehensive error form]. The majority of explanations for deviating results were found in methodological problems (39.4%), followed by technical problems (33.7%), clerical errors (21.2%) or other problems (5.8%). No laboratory reported equipment problems or organizational factors as the explanation for deviating results. As can be seen in Table 3 , frequently reported sources of error related to problems with the analysis of low concentrations were the concentration of the antifungal drug being below the lower limit of quantification (LLOQ; 11.5% of inaccuracies) and imprecision due to the result being close to the lower limit of detection (LLOD; 15.4%). Five year results of a PT programme for antifungal drugs 2991 
JAC
Discussion
The purpose of our PT programme is to provide external assessment of a laboratory's analytical performance in the measurement of antifungal drugs, thereby alerting the participating laboratory to potential problems. To our knowledge, we are the first independent institution organizing an international PT programme for the measurement of six antifungal drugs in varying analytical concentrations. Recently, the UK National External Quality Assessment Service (UK NEQAS) has set up a similar programme with a comparable objective, but this covers fewer antifungal agents (voriconazole, posaconazole and (hydroxy)itraconazole). 15 Our results over a 5 year period show that almost one-fifth (19.2%) of antifungal drug measurements in the PT programme were inaccurate. The performing laboratory was the only factor clearly related to the absolute inaccuracy based on descriptive analysis and ANOVA, although descriptive analysis and evaluation of error forms suggested that lower concentrations may be related to inaccuracies as well.
A total of 19.2% inadequate analyses is considered displeasingly suboptimal, as this may be a source of bias in pharmacokinetic studies performed by these laboratories and could influence the clinical decision making following TDM, ultimately leading to therapy failure or concentration-related toxicity. Moreover, although an overall median absolute inaccuracy of 8.0% may be considered acceptable, the range of 0% -3340% indicates that measurement of antifungal drugs needs improvement in a number of laboratories.
Based on our analysis of 5 year data, the performing laboratory was the only factor clearly related to inaccuracies in the measurement of antifungal drugs. This probably means that internal (intralaboratory) quality assurance, as reflected in adequate validation of assays, validation of equipment and qualification of technicians, is the main determinant of inaccuracy. In other words, accurate results can be obtained with sufficient internal quality assurance, irrespective of the antifungal drug to be measured, its concentration and the analytical equipment available.
Apart from this, descriptive analysis of dichotomized results and evaluation of error forms suggested that laboratories do encounter problems when analysing lower concentrations. This may be considered as a reflection of insufficient internal quality assurance as well (e.g. inadequate range of the method and suboptimal validation of the limit of quantification). Difficulty with lower concentrations is in line with our previous findings 11 and with findings in other PT programmes. 16, 17 As trough concentrations of antifungal drugs are considered the most reliable predictor of therapeutic efficacy, 18 laboratories should put extra effort into measuring low concentrations.
Alerting the laboratories to inaccuracies and despatching error forms regarding inadequate performance supported the identification of possible sources of error. It was reported that methodological problems were the greatest source of error (39.4%; Table 3 ). This is in line with results from other PT programmes, 19 -22 which also reported methodological errors as being responsible for most of the inadequate results in their programmes (28%, 31%, 33% and 51%, respectively). Again, error forms suggested that analysis of lower concentrations is a problem, as most of the methodological problems were caused by an imprecise analysis due to a concentration close to the LLOD (15.4%) and laboratories also encountered technical problems due to the concentration of the antifungal drug being below the LLOQ (11.5%; Table 3 ). We assume that these laboratories have developed an assay with a higher LLOQ or LLOD than the concentrations generally achieved in clinical practice (Table 1) .
Even though clerical errors seem to be avoidable, they remain another major source of error for inadequate results (21.2%; Table 3 ).
Fortunately, the PT programme (including the despatching of error forms) is available to alert laboratories to inaccuracies and to previously undetected problems. In view of the low percentage of unexplained or unassigned causes for inaccuracies as reported by the error forms (5.8%), corrective action could lead to improved performance over time, ultimately enhancing accuracy for everyday samples.
Indeed, over 5 years, the percentage of accurate analyses of all laboratories participating from 2008 until 2012 gradually improved from 71.0% to 87.7%. This was in line with a progressive decrease in median absolute inaccuracy of all drugs from 12.0% (2008) to 6.4% (2012), indicating a possible contribution of our programme to a more adequate analysis of antifungal drugs ( Figure 1 ). It should be noted that overall performance of the laboratories over time is difficult to interpret because of changing numbers of participating laboratories per year. For instance, experienced laboratories possibly withdrew from the programme due to repetitive good results or new laboratories were included once they had their assay operational. To make a valid statement of improvement over time we performed the analysis only with those laboratories that participated throughout the complete period of the programme.
The programme in its current form was developed to represent the real-life performance of the participating laboratory as closely as possible. Therefore, we used human plasma instead of lyophilized plasma, which needs to be reconstituted. Moreover, no reference substrates or plasma samples were distributed. Nevertheless, there are still some aspects to consider. By adding all antifungal drugs to a single sample, laboratories using bioassays are precluded. Furthermore, as indicated by the error forms (various problems; see Table 3 ), some laboratories encounter interference from other antifungal drugs during their analyses (e.g. hydroxyitraconazole interfering with posaconazole analysis). In our opinion, this reflects an analytical method that was not adequately validated for specificity/selectivity. Thus, a combined sample of antifungal drugs assists in the resolution of adequate specificity and selectivity of the method of analysis. This is specifically needed when patients switch antifungal therapy in the clinical setting.
There is a general consideration with regard to the programme. As many laboratories use their analytical assay for the purpose of TDM, it could be interesting to interpret inaccuracies in relation to clinical breakpoints. Unfortunately, clinical breakpoints of antifungal drugs are still subject to debate and furthermore are determined by the MIC of the causative pathogen, making this approach somewhat complicated. In addition, the programme can also be used for improving an analytical method used in the setting of pharmacokinetic research. Here clinical breakpoints are not an issue. Hence, we decided to refrain from using clinical concentrations for the interpretation of results as this would not be straightforward, and to restrict ourselves to using the conventional analytical concentrations.
From the questionnaire it was noted that several laboratories reported problems measuring low concentrations due to the Lempers et al.
fact that their LLOQ was above the weighed-in concentration. We have chosen to define such concentrations below the LLOQ as inaccurate. This approach can be debated. Some laboratories developed an assay with an LLOQ that was close to the lower target concentrations when used for TDM. Obviously, these assays have a greater chance of poor performance for low concentrations (concentrations below the LLOQ), resulting in inaccurate measurement. It should be stressed once more that this PT programme is instituted for the purpose not only of TDM but also of achieving a sound quality of analytical assay regardless of its intended goal. Setting an LLOQ low enough is a prerequisite for good performance when the purpose is for pharmacokinetic research. Therefore, we felt it was justified to classify concentrations below the LLOQ as inaccurate.
In summary, the 5 year results of our PT programme indicate that the analysis of antifungal drug concentrations in plasma is complex and that improvement is warranted for several laboratories. In view of the results of the PT programme and the growing number of participating laboratories, there is a clear need for such a PT programme. In the future, more antifungal drugs will be added to the programme (e.g. echinocandins). Based on the high percentage of inaccurate results and their subsequent clinical implications, laboratories can improve the measurement of their antifungal drug concentrations by participation in the PT programme and they are invited to subscribe (see www.kkgt.nl).
